[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20220490T8 - Spojevi tiazolidinona i njihova upotreba u liječenju psihijatrijskih ili neuroloških poremećaja i inflamacije, posebno neuroinflamacije - Google Patents

Spojevi tiazolidinona i njihova upotreba u liječenju psihijatrijskih ili neuroloških poremećaja i inflamacije, posebno neuroinflamacije

Info

Publication number
HRP20220490T8
HRP20220490T8 HRP20220490TT HRP20220490T HRP20220490T8 HR P20220490 T8 HRP20220490 T8 HR P20220490T8 HR P20220490T T HRP20220490T T HR P20220490TT HR P20220490 T HRP20220490 T HR P20220490T HR P20220490 T8 HRP20220490 T8 HR P20220490T8
Authority
HR
Croatia
Prior art keywords
psychiatric
inflammation
treatment
neurological disorders
thiazolidinone compounds
Prior art date
Application number
HRP20220490TT
Other languages
English (en)
Inventor
Jean-Louis Reymond
Simon NICOLUSSI
Jürg Gertsch
Original Assignee
Universität Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Bern filed Critical Universität Bern
Publication of HRP20220490T1 publication Critical patent/HRP20220490T1/hr
Publication of HRP20220490T8 publication Critical patent/HRP20220490T8/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54Nitrogen and either oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HRP20220490TT 2014-05-28 2015-05-28 Spojevi tiazolidinona i njihova upotreba u liječenju psihijatrijskih ili neuroloških poremećaja i inflamacije, posebno neuroinflamacije HRP20220490T8 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14170449 2014-05-28
EP14171024 2014-06-03
PCT/EP2015/061915 WO2015181337A1 (en) 2014-05-28 2015-05-28 Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
EP15725042.4A EP3148990B1 (en) 2014-05-28 2015-05-28 Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation

Publications (2)

Publication Number Publication Date
HRP20220490T1 HRP20220490T1 (hr) 2022-05-27
HRP20220490T8 true HRP20220490T8 (hr) 2022-06-10

Family

ID=54698145

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220490TT HRP20220490T8 (hr) 2014-05-28 2015-05-28 Spojevi tiazolidinona i njihova upotreba u liječenju psihijatrijskih ili neuroloških poremećaja i inflamacije, posebno neuroinflamacije

Country Status (15)

Country Link
US (3) US10155754B2 (hr)
EP (2) EP4011879A1 (hr)
JP (1) JP6671301B2 (hr)
CN (1) CN106660976B (hr)
AU (2) AU2015265865B2 (hr)
BR (1) BR112016027901B1 (hr)
CA (1) CA2950354C (hr)
DK (1) DK3148990T3 (hr)
ES (1) ES2910455T3 (hr)
HR (1) HRP20220490T8 (hr)
MX (2) MX2016015627A (hr)
PL (1) PL3148990T3 (hr)
RS (1) RS63107B1 (hr)
RU (1) RU2734253C2 (hr)
WO (1) WO2015181337A1 (hr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181336A1 (en) * 2014-05-28 2015-12-03 Universität Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798067A (en) * 1954-03-29 1957-07-02 Eastman Kodak Co 2-imino-4-thiazolidones and preparation
US2739888A (en) * 1954-03-29 1956-03-27 Eastman Kodak Co Photographic elements containing thiazolidine derivatives
AU2003298693B2 (en) * 2002-11-22 2010-09-30 Smithkline Beecham Corporation Novel chemical compounds
EP1660459A2 (en) * 2003-08-12 2006-05-31 Amgen inc. Arylsulfonamidobenzylic compounds
EP1654380A4 (en) * 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
EP1689726B1 (en) * 2003-11-21 2010-10-06 Actelion Pharmaceuticals Ltd. 5-(benz- (z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents
EP1959958A4 (en) 2005-11-14 2010-07-14 Univ Southern California INTEGRIN-BINDING SMALL MOLECULES
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
WO2009137133A2 (en) * 2008-02-14 2009-11-12 University Of Washington 5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection
WO2010136221A1 (en) 2009-05-29 2010-12-02 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Dodeca-2e,4e-diene amides and their use as medicaments and cosmetics
GB201007187D0 (en) * 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators

Also Published As

Publication number Publication date
AU2015265865B2 (en) 2020-05-07
RU2016147230A3 (hr) 2018-12-25
EP3148990A1 (en) 2017-04-05
US20190382397A1 (en) 2019-12-19
AU2020213369B2 (en) 2022-09-22
US10774077B2 (en) 2020-09-15
RU2016147230A (ru) 2018-07-02
RU2734253C2 (ru) 2020-10-13
CA2950354C (en) 2023-10-03
HRP20220490T1 (hr) 2022-05-27
MX2016015627A (es) 2017-05-04
JP2017516795A (ja) 2017-06-22
DK3148990T3 (da) 2022-04-11
CN106660976A (zh) 2017-05-10
EP3148990B1 (en) 2022-01-19
AU2015265865A1 (en) 2016-12-15
ES2910455T3 (es) 2022-05-12
US20170197952A1 (en) 2017-07-13
CN106660976B (zh) 2019-11-26
BR112016027901B1 (pt) 2023-12-12
CA2950354A1 (en) 2015-12-03
RS63107B1 (sr) 2022-04-29
MX2020013537A (es) 2021-02-26
EP4011879A1 (en) 2022-06-15
JP6671301B2 (ja) 2020-03-25
US10155754B2 (en) 2018-12-18
US20190119265A1 (en) 2019-04-25
BR112016027901A2 (pt) 2017-08-22
AU2020213369A1 (en) 2020-08-27
US10392377B2 (en) 2019-08-27
WO2015181337A1 (en) 2015-12-03
PL3148990T3 (pl) 2022-05-30

Similar Documents

Publication Publication Date Title
IL279752A (en) Polycyclic compounds and their use in the treatment of immune disorders
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
IL247841A0 (en) Heterocyclic compounds for use in the treatment of disorders mediated by pi3k gamma
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
IL246855A0 (en) Materials for use in the treatment of retinitis
IL275349A (en) Use of hM4Di in the treatment of seizure disorders
EP3371154A4 (en) HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
PL3148990T3 (pl) Związki tiazolidynonu i ich zastosowanie w leczeniu zaburzeń psychiatrycznych neurologicznych i stanów zapalnych, w szczególności stanów zapalnych układu nerwowego
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
PT3148990T (pt) Compostos de tiazolidinona e seu uso no tratamento de condições psiquiátricas ou distúrbios neurológicos e inflamação, particularmente neuroinflamação
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
GB201603510D0 (en) Compositions for use in the treatment of neurological disease